Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism

Part i (Factor Xa inhibitors)

Rohtesh S Mehta

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and would potentially soon revolutionize coagulation medicine. The first part of this article reviews oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban and YM150 - exploring the outcomes of major clinical trials for prophylaxis and treatment of venous thromboembolism - and also briefly outlining their pharmacological properties. The second part of the article (in a separate issue) will cover oral Factor IIa (thrombin), such as dabigatran and AZD0837 and oral Factor IX inhibitors, such as TTP889.

Original languageEnglish (US)
Pages (from-to)227-241
Number of pages15
JournalExpert Review of Hematology
Volume3
Issue number2
DOIs
StatePublished - Apr 1 2010

Fingerprint

Factor IX
Venous Thromboembolism
Thrombin
Anticoagulants
Medicine
Clinical Trials
Pharmacology
AZD 0837
edoxaban
apixaban
Dabigatran
Rivaroxaban
Factor IIa
Factor Xa Inhibitors

Keywords

  • Blood thinners
  • Deep vein thrombosis
  • Direct thrombin inhibitors
  • Factor Xa inhibitors
  • Heparin alternatives
  • Hip replacement prophylaxis
  • Knee replacement prophylaxis
  • Novel anticoagulants
  • Oral anticoagulants
  • Prophylaxis deep vein thrombosis

Cite this

Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism : Part i (Factor Xa inhibitors). / Mehta, Rohtesh S.

In: Expert Review of Hematology, Vol. 3, No. 2, 01.04.2010, p. 227-241.

Research output: Contribution to journalReview article

@article{65a5a37f80cc429487b66881be411330,
title = "Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: Part i (Factor Xa inhibitors)",
abstract = "The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and would potentially soon revolutionize coagulation medicine. The first part of this article reviews oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban and YM150 - exploring the outcomes of major clinical trials for prophylaxis and treatment of venous thromboembolism - and also briefly outlining their pharmacological properties. The second part of the article (in a separate issue) will cover oral Factor IIa (thrombin), such as dabigatran and AZD0837 and oral Factor IX inhibitors, such as TTP889.",
keywords = "Blood thinners, Deep vein thrombosis, Direct thrombin inhibitors, Factor Xa inhibitors, Heparin alternatives, Hip replacement prophylaxis, Knee replacement prophylaxis, Novel anticoagulants, Oral anticoagulants, Prophylaxis deep vein thrombosis",
author = "Mehta, {Rohtesh S}",
year = "2010",
month = "4",
day = "1",
doi = "10.1586/ehm.10.5",
language = "English (US)",
volume = "3",
pages = "227--241",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism

T2 - Part i (Factor Xa inhibitors)

AU - Mehta, Rohtesh S

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and would potentially soon revolutionize coagulation medicine. The first part of this article reviews oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban and YM150 - exploring the outcomes of major clinical trials for prophylaxis and treatment of venous thromboembolism - and also briefly outlining their pharmacological properties. The second part of the article (in a separate issue) will cover oral Factor IIa (thrombin), such as dabigatran and AZD0837 and oral Factor IX inhibitors, such as TTP889.

AB - The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and would potentially soon revolutionize coagulation medicine. The first part of this article reviews oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban and YM150 - exploring the outcomes of major clinical trials for prophylaxis and treatment of venous thromboembolism - and also briefly outlining their pharmacological properties. The second part of the article (in a separate issue) will cover oral Factor IIa (thrombin), such as dabigatran and AZD0837 and oral Factor IX inhibitors, such as TTP889.

KW - Blood thinners

KW - Deep vein thrombosis

KW - Direct thrombin inhibitors

KW - Factor Xa inhibitors

KW - Heparin alternatives

KW - Hip replacement prophylaxis

KW - Knee replacement prophylaxis

KW - Novel anticoagulants

KW - Oral anticoagulants

KW - Prophylaxis deep vein thrombosis

UR - http://www.scopus.com/inward/record.url?scp=77953380083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953380083&partnerID=8YFLogxK

U2 - 10.1586/ehm.10.5

DO - 10.1586/ehm.10.5

M3 - Review article

VL - 3

SP - 227

EP - 241

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -